BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, announced that it will hold a conference call on Thursday, January 30, at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST).
According to a release, Chaim Lebovits, President and Principal Executive Officer of BrainStorm, will update shareholders on the latest developments in the company's clinical trials program, and other business developments. He will be joined by Professor Dimitrios Karussis, Principal Investigator at Hadassah Medical Center, Dr. Moshe Neuman, President and CEO of Biomedical Research Design and CRO of BrainStorm's clinical trials at Hadassah, Curtis Head, President and CEO of PRC Clinical and CRO of BrainStorm's clinical trials in the USA, and Professor Paulo Brofman, Director of the Cell Technology Center at the Pontifical Catholic University of Parana in Brazil. The call will be conducted in English. Callers may participate in the conference call by dialing:
The company reported that callers are invited to ask relevant questions in English during the conference call. Questions may also be pre-submitted to email@example.com by 5 p.m. EST Wednesday, January 29.
Additionally, a recording of the conference call will be posted by Friday, January 31, on the company's website.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology
Conference call information:
((Comments on this story may be sent to firstname.lastname@example.org))